Welcome to our dedicated page for Oruka Therapeutics SEC filings (Ticker: ORKA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oruka Therapeutics, Inc. (NASDAQ: ORKA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, financial statements, and material agreements. As a Nasdaq-listed clinical-stage biotechnology company focused on biologic therapies for chronic skin diseases, Oruka uses its SEC filings to report key corporate, financial, and governance information related to its psoriasis and inflammatory disease programs.
Investors can review Form 8-K current reports where Oruka describes material events such as private placement financings, changes in directors and executive officers, and the terms of securities purchase agreements and registration rights agreements. These filings also document board appointments, committee roles, director compensation, and equity awards, providing detail on corporate governance and leadership transitions.
Periodic reports such as Form 10-Q and Form 10-K (when available) contain condensed consolidated financial statements, including research and development and general and administrative expenses, net losses, cash, cash equivalents, and marketable securities. For a clinical-stage company like Oruka, these filings help readers understand the level of investment in plaque psoriasis and other dermatologic programs, as well as the company’s capital position and runway assumptions.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points, such as trial-related disclosures, financing structures, and changes in share count. Users can also access information related to equity issuances and warrant terms, and track how Oruka’s capital structure evolves over time. Real-time updates from EDGAR ensure that new ORKA filings, including any future proxy statements or insider transaction reports on Form 4, appear promptly with plain-language explanations to support more efficient review.
Fairmount-affiliated funds filed Amendment No. 5 to their Schedule 13D on Oruka Therapeutics, Inc. to disclose a new lock-up agreement while keeping their reported ownership unchanged. Fairmount Funds Management LLC and related entities report beneficial ownership of 13,665,080 shares of common stock, representing 19.99% of Oruka’s common stock based on 68,359,627 shares outstanding as of April 30, 2026.
The position includes common shares and shares issuable upon conversion of Series B non-voting convertible preferred stock, subject to a 19.99% beneficial ownership limitation. Additional 5,297,664 warrant shares and 1,468,331 shares issuable from Series B preferred are excluded because of 9.99% and 19.99% ownership caps.
In connection with Oruka’s underwritten public offering that closed on April 30, 2026, the reporting persons entered into a customary lock-up letter with the underwriters, agreeing not to sell company securities for 45 calendar days from the date of the underwriting agreement, unless Leerink Partners consents. They did not purchase securities or otherwise participate in the offering.
Oruka Therapeutics, Inc. Chief Operating Officer Laura Lee Sandler reported multiple transactions in the company’s common stock. On May 1, 2026, she completed open-market sales totaling 5,000 shares at weighted average prices within ranges from $62.33 to $67.20 per share under a pre-established Rule 10b5-1 trading plan.
On the same date, she also exercised employee warrants to acquire 5,000 shares of common stock at an exercise price of $7.80 per share. The warrant covers 5,000 underlying shares, vests over time beginning April 3, 2025, and is scheduled to expire on July 14, 2034.
Laura Sandler submitted a Form 144 notice to sell 10,000 shares of Common stock on 05/01/2026. The filing lists the proposed sale as resulting from an Exercise of Stock Options with cash consideration. The record also shows prior 10b5-1 sales of 5,000 shares for $167,821.50 on 03/02/2026 and 600 shares for $24,780.00 on 03/16/2026.
Oruka Therapeutics, Inc. reported preliminary first-quarter data and the closing of a common stock offering. The company estimates its cash, cash equivalents, and investments were approximately $496 million as of March 31, 2026, based on management’s internal data and subject to final accounting.
Oruka completed an underwritten public offering of 9,660,000 shares of common stock at $72.50 per share, made from its effective shelf registration statement. The underwriters also received a 30-day option to purchase up to an additional 1,449,000 shares at the same public offering price, less underwriting discounts and commissions. The company emphasizes that the preliminary cash figure is unaudited and should not be relied on as final results.
Oruka Therapeutics, Inc. is offering 9,660,000 shares of common stock at an offering price of $72.50 per share pursuant to this prospectus supplement. Net proceeds are estimated at approximately $658.2 million, and the underwriters have a 30‑day option to purchase up to an additional 1,449,000 shares at the public offering price less underwriting discounts and commissions. The number of shares outstanding after the offering is expected to be 58,382,309 (or 59,831,309 if the underwriters exercise their option in full). The prospectus supplement states a preliminary cash, cash equivalents and investments balance of approximately $496 million as of March 31, 2026. Proceeds are intended for general corporate purposes, including research and development and working capital. The offering is conducted under a shelf registration and includes customary underwriting discounts, a 45‑day issuer lock‑up and standard international selling restrictions.
Oruka Therapeutics, Inc. is pursuing a primary offering of its common stock under a shelf prospectus supplement subject to completion. The prospectus does not state the number of shares or offering size; net proceeds are intended for general corporate purposes, including research and development and working capital. The company reported approximately $496 million in cash, cash equivalents and investments as of March 31, 2026, and had 48,722,309 shares of common stock outstanding as of December 31, 2025. The common stock trades on Nasdaq under the symbol ORKA and the prospectus includes customary underwriting terms, a 30-day option to purchase additional shares, a 45-day lock-up period for insiders, and standard offering risk disclosures.
Oruka Therapeutics, Inc. is offering securities under a preliminary prospectus supplement related to a shelf registration covering up to $500,000,000 of common stock and pre-funded warrants. The offering includes common stock and pre-funded warrants exercisable at $0.001 per share, with the shares issuable upon exercise registered here.
The prospectus supplement states 48,722,309 shares outstanding as of December 31, 2025 and discloses a preliminary cash, cash equivalents and investments balance of approximately $496 million as of March 31, 2026. Net tangible book value was reported as $471.9 million, or $9.69 per share, as of December 31, 2025. The offering proceeds treatment is described as for general corporate purposes, including research and development and working capital.
Oruka Therapeutics reported interim Phase 2a EVERLAST-A results for ORKA-001 in moderate-to-severe plaque psoriasis, showing 63.5% (40/63) of treated patients reached PASI 100, versus 4.8% (1/21) on placebo at Week 16.
Secondary measures were similarly strong, with 82.5% achieving PASI 90 and 84.1% reaching IGA 0/1. ORKA-001’s safety profile was comparable to placebo, with no serious treatment-emergent adverse events in the active arm and no injection site reactions. Phase 1 pharmacokinetic and pharmacodynamic data indicate drug levels and IL‑23 pathway inhibition remain above effective thresholds for a year after a single 600 mg dose, supporting potential once‑yearly dosing. The EVERLAST-A trial continues, with longer-term durability and safety data expected in the second half of 2026, while the dose-ranging Phase 2b EVERLAST-B study is enrolling, with results anticipated in 2027.
ORKA filed a prospectus supplement to amend the selling stockholders table: the resale registration still covers 39,425,806 shares of Common Stock, and SILV Fund Ltd. is substituted for Point72 Associates, LLC as a selling stockholder. The supplement cites 49,542,691 shares outstanding as of February 28, 2026 for percentage calculations and shows 531,670 shares listed for SILV Fund Ltd. The supplement does not increase the number of shares registered and repeats the stated market price of $68.87 per share (last reported sale on April 20, 2026).